Overview

Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy

Status:
Completed
Trial end date:
2016-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to assessed the efficiency of treatment based on the objective response rate (RECIST 1.1)
Phase:
Phase 2
Details
Lead Sponsor:
Gustave Roussy, Cancer Campus, Grand Paris
Treatments:
Bevacizumab
Capecitabine
Irinotecan